摘要
用术中肝动脉栓塞化疗联合门静脉栓塞化疗治疗不能切除的原发性肝癌 32例 ,治疗后 AFP下降率为 78.3% ,肿瘤缩小率为 90 .6% ,半年、1年、2年生存率分别为 90 .6%、79.3%、52 .1% ;而同期行经皮股动脉插管肝动脉栓塞化疗治疗 30例 ,治疗后 AFP下降率为 57.1% ,肿瘤缩小率为 66.7% ,半年、1年、2年生存率分别为 70 .0 %、57.1% |16.7% ,两组 AFP下降率 ,肿瘤缩小率 ,半年、1年、2年生存率经统计学检验均有显著性差异 (P值均〈0 .0 5)。术中肝动脉栓塞化疗后 ,因肿瘤缩小而行二期切除的 3例 ,病理检查表现为肿瘤形成包膜 ,肿瘤组织坏死并纤维化 ,肿瘤周边组织未见癌细胞。提示此联合疗法疗效确切 ,操作简便 ,不需特殊器械 ,术中高选插管准确 ,异位栓塞等并发症少 ,能及时做病理检查 ,减少误诊误治 ,是治疗不能切除的原发性肝癌的好方法。
Thirty-two cases with nonresectable primary liver cancer were treated by a combination of intraoperative hepatic arterial chemoembolization (IOHACE) and portal venous chemoembolization After the treatment,AFP level in 78 3% cases declined,the rate of tumor shrinkage was 90 6% Half year,one and two year survival rate were 90 6%,79 3% and 52 1% respectively While thirty curases were treated by transcatheter arterial chemoembolization(TACE),AFP level in 57 1% cases declined, the rate of tumor shrinkage was 66 7% Half year,one and two year survival rate were 70 0%,57 1% and 16 7% There was significantly difference between the two groups (P<0 05) It is suggested that a combination of IOHACE and PVCE is a reliable method for the treatment of the patient with nonresectable primary liver cancer
出处
《广西医学》
CAS
1999年第6期1085-1088,共4页
Guangxi Medical Journal
关键词
肝肿瘤
术中
肝动脉栓塞
药物疗法
Liver neoplasms
Intraoperative hepatic arterial chemoembolization
Portal venous chemoembolization
